Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RDD: Optimizing Retention and Discontinuation Strategies for OUD
NCT04464980Phase 2Active, not recruiting
- Sponsor
- NYU Langone Health
- Start
- Jun 2021
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine extended-release injection, naltrexone in opioid use disorder (OUD), sponsored by NYU Langone Health. Started Jun 2021; status: active, not recruiting.
02
Drugs
buprenorphine extended-release injectionnaltrexone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04464980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464980.